These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 3080526

  • 1. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES.
    J Immunol; 1986 Feb 15; 136(4):1510-5. PubMed ID: 3080526
    [Abstract] [Full Text] [Related]

  • 2. The antimetastatic function of concomitant antitumor immunity. I. Host Ly-1+2+ effector T cells prevent the enumeration of metastatic tumor cells in a biological assay.
    Dye SE.
    J Immunol; 1986 Feb 15; 136(4):1504-9. PubMed ID: 3080525
    [Abstract] [Full Text] [Related]

  • 3. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 4. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
    Mills CD, North RJ.
    J Exp Med; 1983 May 01; 157(5):1448-60. PubMed ID: 6189937
    [Abstract] [Full Text] [Related]

  • 5. In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice.
    Tuttle RL, Knick VC, Stopford CR, Wolberg G.
    Cancer Res; 1983 Jun 01; 43(6):2600-5. PubMed ID: 6133611
    [Abstract] [Full Text] [Related]

  • 6. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN, Williams RM, Benacerraf B.
    Am J Pathol; 1976 Dec 01; 85(3):661-74. PubMed ID: 826167
    [Abstract] [Full Text] [Related]

  • 7. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov 01; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 9. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr 01; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

  • 10. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY, Chou T, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):295-304. PubMed ID: 2953816
    [Abstract] [Full Text] [Related]

  • 11. In vivo activity of lymphokine-activated macrophages in host defense against neoplasia.
    Fernandez-Cruz E, Ulich T, Schreiber RD.
    J Immunol; 1985 May 01; 134(5):3489-96. PubMed ID: 3920323
    [Abstract] [Full Text] [Related]

  • 12. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K, Chang AE, Shu SY.
    Cancer Res; 1990 Jul 15; 50(14):4371-6. PubMed ID: 2114215
    [Abstract] [Full Text] [Related]

  • 13. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2895-903. PubMed ID: 2411817
    [Abstract] [Full Text] [Related]

  • 14. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
    Niederkorn JY, Streilein JW.
    J Immunol; 1983 Nov 15; 131(5):2587-94. PubMed ID: 6415174
    [Abstract] [Full Text] [Related]

  • 15. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
    Yang G, Mizuno MT, Hellström KE, Chen L.
    J Immunol; 1997 Jan 15; 158(2):851-8. PubMed ID: 8993003
    [Abstract] [Full Text] [Related]

  • 16. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S, Ksander B, Streilein JW.
    Reg Immunol; 1992 Jan 15; 4(6):352-62. PubMed ID: 1297406
    [Abstract] [Full Text] [Related]

  • 17. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA, Walker MC, Phillips-Quagliata JM.
    Cancer Res; 1986 Jan 15; 46(1):190-7. PubMed ID: 3484380
    [Abstract] [Full Text] [Related]

  • 18. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E, Baral E, Kangas L, Berczi I.
    Anticancer Res; 1997 Jan 15; 17(2A):1083-8. PubMed ID: 9137453
    [Abstract] [Full Text] [Related]

  • 19. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB.
    J Immunol; 1998 Dec 15; 161(12):6552-8. PubMed ID: 9862681
    [Abstract] [Full Text] [Related]

  • 20. Degradation of specificity in cytolytic T lymphocyte clones. The separate YAC-1-type (NK-like) and P815-type broad specificity killing patterns are both restricted to the larger cells within a clone but may be expressed independently in clones from different mouse strains.
    Shortman K, Wilson A.
    J Immunol; 1986 Aug 01; 137(3):798-804. PubMed ID: 2424983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.